Ibrutinib Combination Therapy Extremely Well Tolerated in Early Trial

Ibrutinib Combination Therapy Extremely Well Tolerated in Early Trial

User Photo
ASHReport

4 years
755 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Jennifer Brown, MD of Dana Farber, discusses a current and promising trial that combines ibrutinib with a standard chemo-immunotherapy combination: fludarabine, cyclophosphamide, rituximab (FCR), at the 58th ASH Annual Meeting in San Diego, CA.
Up Next Autoplay
>